Skip to main content

Table 1 Baseline characteristics of patients using pregabalin

From: Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

 Number
(percentage)
No. of patients114,437
Male48,316 (42.2)
Age, mean (SD), year60.66 (15.4)
Monthly income NT$
NT 0–21,00936,963 (32.3)
NT 210,10-36,82552,546 (45.9)
> 36,82524,928 (21.8)
Region of Taiwan
Northern region49,791 (43.5)
Central region33,899 (29.6)
Southern region27,122 (23.7)
Eastern region3625 (3.2)
Charlson Comorbidity Index score
039,922 (34.9)
126,902 (23.5)
2–434,764 (30.4)
> 412,849 (11.2)
Specialties
Neurology53,910 (47.1)
Anesthesiology5541 (4.8)
Physiatry3151 (2.8)
Psychiatry430 (0.4)
Rheumatology9201 (8.0)
Others42,204 (36.9)
Indications
Herpes zoster34,919 (30.5)
Diabetic peripheral neuropathic pain13,369 (11.7)
Fibromyalgia21,051 (18.4)
Epilepsy3301 (2.9)
Other musculoskeletal diseases24,227 (21.2)
Others17,570 (15.4)
Concomitant medications
Gabapentin14,114 (12.3)
Duloxetine4410 (3.9)
NSAIDs68,679 (60)
Acetaminophen45,834 (40.1)
Tramadol5011 (4.4)
Acetaminophen/tramadol31,777 (27.8)
Lidocaine medicated plaster1114 (1.0)
Anti-viral agentsa6625 (5.8)
Daily dosage
< 75 mg1162 (1.0)
75-149 mg57,106 (49.9)
150-224 mg50,925 (44.5)
> =225 mg5244 (4.6)
  1. aIncluding valaciclovir, ganciclovir, famciclovir, and acyclovir
\